Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-06: Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric/GEJ cancer
jRCT2031220162Phase 3Completed
- Sponsor
- ALX Oncology
- Start
- Aug 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of evorpacept in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by ALX Oncology. Started Aug 2022; status: completed.
02
Drugs
evorpacept
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220162.